NCT06112990 (CREATINE-52) is a Phase 3 clinical trial of creatine monohydrate in Metastatic Prostate Cancer, sponsored by University of Utah.

Who is sponsoring NCT06112990?

NCT06112990 is sponsored by University of Utah.

What drugs are being tested in NCT06112990?

Interventions in NCT06112990: creatine monohydrate, Placebo, Home-based, telehealth.

What condition does NCT06112990 study?

NCT06112990 studies Metastatic Prostate Cancer.

Is NCT06112990 still recruiting?

NCT06112990 is currently recruiting now. Last updated 16 April 2025.

Last reviewed 2025-04-16 · How we verify

NCT06112990: CREATINE-52

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Creatine Supplementation and Resistance Training to Preserve Muscle Mass and Attenuate Cancer Progression

Recruiting now Phase 3 Last updated 16 April 2025

What this trial tests

Phase 3 trial testing creatine monohydrate in Metastatic Prostate Cancer in 200 participants. Currently enrolling.

Timeline

9 November 2023

Primary endpoint
30 November 2028

30 November 2028

Quick facts

Lead sponsor	University of Utah
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	200
Start date	9 November 2023
Primary completion	30 November 2028
Estimated completion	30 November 2028
Sites	1 location across United States

Drugs / interventions tested

creatine monohydrate — full drug profile →
Placebo
Home-based, telehealth

Conditions studied

Metastatic Prostate Cancer — all drugs for Metastatic Prostate Cancer →

Sponsor

University of Utah

Who can join

18 and older, male only, with Metastatic Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to test the use of creatine monohydrate supplementation with resistance training to preserve muscle mass and help lessen prostate cancer progression. The main question it aims to answer is if this treatment will help maintain muscle mass to help in reducing fatigue and improving physical function, independence, and quality of life. Participants will be asked to participate in a 52-week exercise intervention consisting of a twice weekly telehealth resistance training program.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Creatine supplementation and resistance training to preserve muscle mass and attenuate cancer progression (CREATINE-52): a protocol for a double-blind randomized controlled trial.
Coletta AM, Simon LH, Maslana K, Taylor S, et al · · 2024 · cited 3× · PMID 38637770 · DOI 10.1186/s12885-024-12260-3

Verify or expand the search:

Other trials of creatine monohydrate

Trials testing the same drug.

NCT04286178 — Exercise, Creatine and Coenzyme Q10 for Childhood Myositis · NA · completed

Other recruiting trials for Metastatic Prostate Cancer

Currently open trials in the same condition.

NCT07145177 — 177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer · Phase 1 · recruiting
NCT07290270 — Real-world Use of Lutetium (177Lu) Vipivotide Tetraxetan in China(PSMAreal CN) · recruiting
NCT07389512 — Pharmaceutical Management in Targeted Radioligand Therapy · recruiting
NCT07209176 — Physician- and Patient-based Barriers to NGS Testing · NA · recruiting
NCT07181161 — Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer · Phase 1, PHASE2 · recruiting

Other University of Utah trials

Trials by the same sponsor.

NCT07515755 — Supplemental Oxygen and Oxygen Desaturations in Colonoscopies · NA · not yet recruiting
NCT07225426 — Personalizing Financial Incentives · NA · recruiting
NCT06716411 — Confirming the Effects of Acupuncture Treatments to Relieve Symptoms of Gulf War Illness · NA · recruiting
NCT07246538 — Positive Airway Pressure (PAP) System Evaluation in Volunteers · NA · not yet recruiting
NCT04208984 — Diversion Device With Breath Control · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06112990 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Utah
Last refreshed: 16 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06112990.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing